Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors

被引:11
|
作者
Methot, Joey L. [1 ]
Achab, Abdelghani [1 ]
Christopher, Matthew [1 ]
Zhou, Hua [1 ]
McGowan, Meredeth A. [1 ]
Trotter, B. Wesley [1 ]
Fradera, Xavier [2 ]
Lesburg, Charles A. [2 ]
Goldenblatt, Peter [3 ]
Hill, Armetta [3 ]
Chen, Dapeng [4 ]
Otte, Karin M. [4 ]
Augustin, Martin [5 ]
Shah, Sanjiv [3 ]
Katz, Jason D. [1 ]
机构
[1] Merck & Co Inc, Discovery Chem, Boston, MA 02115 USA
[2] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[3] Merck & Co Inc, In Vitro Pharmacol, Boston, MA 02115 USA
[4] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Boston, MA 02115 USA
[5] Proteros Biostruct, D-82152 Martinsried, Germany
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 12期
关键词
PI3K delta inhibitor; PI3K alpha selectivity; oxindole; adenosine uptake; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCED VASCULAR INJURY; PI3K INHIBITORS; IN-VITRO; CD69; MECHANISMS; RESPONSES; POTENCY;
D O I
10.1021/acsmedchemlett.0c00441
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 3,3-disubstituted oxindole moiety is a versatile and rigid three-dimensionally shaped scaffold. When engineered with a purine hinge-binding core, exceptionally selective PI3K delta kinase inhibitors were discovered by exploiting small differences in isoform selectivity pockets. Crystal structures of early lead 2f bound to PI3K delta and PI3K alpha helped rationalize the high selectivity observed with 2f. By attenuating the lypophilicity and metabolic liabilities of an oxindole moiety, we improved the preclinical species PK and solubility and reduced adenosine uptake activity. The excellent potency and kinome selectivity of 7-azaoxindole 4d and spirooxindole 5d, together with a low plasma clearance and good half-life in rat and dog, supported a low once-daily predicted human dose.
引用
收藏
页码:2461 / 2469
页数:9
相关论文
共 50 条
  • [31] Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels
    Dan, Shingo
    Sugita, Hironobu
    Yamazaki, Kanami
    Yamori, Takao
    [J]. CANCER RESEARCH, 2009, 69
  • [32] Preclinical profile of novel, potent, and selective PI3K delta inhibitors
    Vakkalanka, Swaroop
    Muthuppalaniappan, Meyyappan
    Babu, G.
    Varanasi, Kanthikiran V. S.
    Veeraraghavan, Sridhar
    Viswanadha, Srikant
    [J]. CANCER RESEARCH, 2011, 71
  • [33] Pharmacokinetics of selective PI3Kδ inhibitors after intratracheal instillation in mice
    Gunerka, Pawel
    Hucz-Kalitowska, Joanna
    Turowski, Pawel
    Zagozda, Marcin
    Dziachan, Maciej
    Sekular, Mariola
    Bujak, Anna
    Wieczorek, Maciej
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [34] A class of highly selective inhibitors bind to an active state of PI3Kγ
    Gangadhara Gangadhara
    Göran Dahl
    Thomas Bohnacker
    Rebecca Rae
    Jenny Gunnarsson
    Stefan Blaho
    Linda Öster
    Helena Lindmark
    Kostas Karabelas
    Nils Pemberton
    Christian Tyrchan
    Mickael Mogemark
    Matthias P. Wymann
    Roger L. Williams
    Matthew W. D. Perry
    Tineke Papavoine
    Jens Petersen
    [J]. Nature Chemical Biology, 2019, 15 : 348 - 357
  • [35] Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors
    de Sousa, Francisca Joseli Freitas
    Azevedo, Francisca Fernanda Nunes
    de Oliveira, Francisco Lucas Santos
    Carletti, Jaqueline Vieira
    Freire, Valder Nogueira
    Zanatta, Geancarlo
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023,
  • [36] A class of highly selective inhibitors bind to an active state of PI3Kγ
    Gangadhara, Gangadhara
    Dahl, Goran
    Bohnacker, Thomas
    Rae, Rebecca
    Gunnarsson, Jenny
    Blaho, Stefan
    Oster, Linda
    Lindmark, Helena
    Karabelas, Kostas
    Pemberton, Nils
    Tyrchan, Christian
    Mogemark, Mickael
    Wymann, Matthias P.
    Williams, Roger L.
    Perry, Matthew W. D.
    Papavoine, Tineke
    Petersen, Jens
    [J]. NATURE CHEMICAL BIOLOGY, 2019, 15 (04) : 348 - +
  • [37] PI3K Inhibitors in Cardiovascular Disease
    Eisenreich, Andreas
    Rauch, Ursula
    [J]. CARDIOVASCULAR THERAPEUTICS, 2011, 29 (01) : 29 - 36
  • [38] Discovery and optimization of a series of benzothiazole PI3K/mTOR dual inhibitors
    D'Angelo, Noel D.
    Kim, Tae-Seong
    Andrews, Kristin
    Booker, Shon K.
    Caenepeel, Sean
    Chen, Kui
    D'Amico, Derin
    Freeman, Dan
    Jiang, Jian
    Liu, Longbin
    McCarter, John D.
    Miguel, Tisha San
    Mullady, Erin L.
    Schrag, Michael
    Subramanian, Raju
    Tang, Jin
    Wahl, Robert C.
    Wang, Ling
    Whittington, Douglas A.
    Wu, Tian
    Xi, Ning
    Xu, Yang
    Yakowec, Peter
    Yang, Kevin
    Zalameda, Leeanne P.
    Zhang, Nancy
    Hughes, Paul
    Norman, Mark H.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [39] Horizons broaden for PI3Kδ inhibitors
    Katie Kingwell
    [J]. Nature Reviews Drug Discovery, 2014, 13 : 573 - 573
  • [40] From lab to clinic: The discovery and optimization journey of PI3K inhibitors
    Lian, Siyu
    Du, Zhenhua
    Chen, Qingqing
    Xia, Yu
    Miao, Xinxin
    Yu, Weiwei
    Sun, Qian
    Feng, Chong
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277